Loading
A phase 2 trial of YL202 should be intravenously infused in non-small-cell lung cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.
A Study of YL202 in Selected Patients With Advanced Solid Tumors is a phase 2 interventional study registered as NCT06107686 by MediLink Therapeutics (Suzhou) Co., Ltd., with 200 participants planned, started 2023-12-15 and due to reach its primary completion in 2026-11. Interventions recorded: YL202 should be intravenously infused.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares YL202, MediLink Therapeutics and the tag pipeline.
Shares MediLink Therapeutics and the tag pipeline.
Shares YL202, MediLink Therapeutics, Non-small-cell lung cancer.
Shares MediLink Therapeutics and the tag pipeline.
Shares MediLink Therapeutics and the tag pipeline.
Shares YL202, MediLink Therapeutics.
Shares MediLink Therapeutics and the tag pipeline.
Shares YL202, MediLink Therapeutics, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/